NO301747B1 - Fremgangsmåte for å fremstille aktivert protein C (APC) - Google Patents

Fremgangsmåte for å fremstille aktivert protein C (APC) Download PDF

Info

Publication number: NO301747B1
Authority: NO; Norway
Prior art keywords: apc; protein; experiments; plasma; thrombin
Prior art date: 1987-11-17

Application number

NO885109A

Other languages

English (en)

Norwegian (no)

Other versions

NO885109D0 (no

NO885109L (no

Inventor

John H Griffin

Andreas Gruber

Stephen R Hanson

Lawrence A Harker

Original Assignee

Scripps Clinic Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-17

Filing date

1988-11-16

Publication date

1997-12-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO301747(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-11-16 Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res

1988-11-16 Publication of NO885109D0 publication Critical patent/NO885109D0/no

1989-05-18 Publication of NO885109L publication Critical patent/NO885109L/no

1997-12-08 Publication of NO301747B1 publication Critical patent/NO301747B1/no

Links

229960000856 protein c Drugs 0.000 title claims abstract description 26
101800004937 Protein C Proteins 0.000 title claims abstract description 25
101800001700 Saposin-D Proteins 0.000 title claims abstract description 25
238000000034 method Methods 0.000 title claims abstract description 13
238000002360 preparation method Methods 0.000 title claims description 7
230000008569 process Effects 0.000 title claims description 3
102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 title abstract 2
239000003527 fibrinolytic agent Substances 0.000 claims abstract description 22
229960000103 thrombolytic agent Drugs 0.000 claims abstract description 22
102000017975 Protein C Human genes 0.000 claims description 23
229960004072 thrombin Drugs 0.000 claims description 8
108090000190 Thrombin Proteins 0.000 claims description 7
108010023197 Streptokinase Proteins 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
229960005202 streptokinase Drugs 0.000 claims description 4
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
102000013566 Plasminogen Human genes 0.000 claims description 2
108010051456 Plasminogen Proteins 0.000 claims description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
229940012957 plasmin Drugs 0.000 claims description 2
108010073863 saruplase Proteins 0.000 claims description 2
108010008962 streptokinase-plasminogen complex Proteins 0.000 claims description 2
229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
229960005356 urokinase Drugs 0.000 claims description 2
230000003213 activating effect Effects 0.000 claims 1
239000012141 concentrate Substances 0.000 claims 1
230000001732 thrombotic effect Effects 0.000 abstract description 6
208000005189 Embolism Diseases 0.000 abstract description 4
208000001435 Thromboembolism Diseases 0.000 abstract description 4
238000002474 experimental method Methods 0.000 description 37
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 22
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 22
230000000694 effects Effects 0.000 description 21
238000001802 infusion Methods 0.000 description 21
239000003146 anticoagulant agent Substances 0.000 description 19
208000007536 Thrombosis Diseases 0.000 description 17
206010003178 Arterial thrombosis Diseases 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 12
230000000740 bleeding effect Effects 0.000 description 12
208000032843 Hemorrhage Diseases 0.000 description 11
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
208000034158 bleeding Diseases 0.000 description 11
230000008021 deposition Effects 0.000 description 11
229960002897 heparin Drugs 0.000 description 11
229920000669 heparin Polymers 0.000 description 11
239000007943 implant Substances 0.000 description 11
230000002785 anti-thrombosis Effects 0.000 description 10
238000003556 assay Methods 0.000 description 10
210000002381 plasma Anatomy 0.000 description 10
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 8
239000000106 platelet aggregation inhibitor Substances 0.000 description 8
229940127218 antiplatelet drug Drugs 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
229920004934 Dacron® Polymers 0.000 description 6
241000282520 Papio Species 0.000 description 6
230000003024 amidolytic effect Effects 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
239000005020 polyethylene terephthalate Substances 0.000 description 6
230000002537 thrombolytic effect Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
206010038563 Reocclusion Diseases 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
229940127219 anticoagulant drug Drugs 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229960004676 antithrombotic agent Drugs 0.000 description 4
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
102000055691 human APC Human genes 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000002792 vascular Effects 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
241001504519 Papio ursinus Species 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000020764 fibrinolysis Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
229920000260 silastic Polymers 0.000 description 3
108010026668 snake venom protein C activator Proteins 0.000 description 3
230000002885 thrombogenetic effect Effects 0.000 description 3
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000282412 Homo Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
206010000891 acute myocardial infarction Diseases 0.000 description 2
230000010100 anticoagulation Effects 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000004087 circulation Effects 0.000 description 2
238000007820 coagulation assay Methods 0.000 description 2
229960000956 coumarin Drugs 0.000 description 2
235000001671 coumarin Nutrition 0.000 description 2
150000004775 coumarins Chemical class 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
230000000322 hemodialysis Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000014508 negative regulation of coagulation Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
229940024790 prothrombin complex concentrate Drugs 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000009424 thromboembolic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010014513 Embolism arterial Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010048849 Myocardial haemorrhage Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
206010073391 Platelet dysfunction Diseases 0.000 description 1
201000005660 Protein C Deficiency Diseases 0.000 description 1
229940122929 Protein C inhibitor Drugs 0.000 description 1
206010043275 Teratogenicity Diseases 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
102100029477 Vitamin K-dependent protein C Human genes 0.000 description 1
101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000000504 antifibrinolytic agent Substances 0.000 description 1
230000006502 antiplatelets effects Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000009125 negative feedback regulation Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000009805 platelet accumulation Effects 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
231100000211 teratogenicity Toxicity 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
External Artificial Organs (AREA)
Investigating Or Analysing Biological Materials (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

NO885109A 1987-11-17 1988-11-16 Fremgangsmåte for å fremstille aktivert protein C (APC) NO301747B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/121,702 US5084274A (en)	1987-11-17	1987-11-17	Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (3)

Publication Number	Publication Date
NO885109D0 NO885109D0 (no)	1988-11-16
NO885109L NO885109L (no)	1989-05-18
NO301747B1 true NO301747B1 (no)	1997-12-08

Family

ID=22398288

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO885109A NO301747B1 (no)	1987-11-17	1988-11-16	Fremgangsmåte for å fremstille aktivert protein C (APC)

Country Status (11)

Country	Link
US (2)	US5084274A (fr)
EP (1)	EP0318201B1 (fr)
JP (1)	JP2766986B2 (fr)
AT (1)	ATE135234T1 (fr)
CA (1)	CA1330036C (fr)
DE (1)	DE3855096T2 (fr)
DK (1)	DK175704B1 (fr)
ES (1)	ES2086301T3 (fr)
FI (1)	FI104790B (fr)
GR (1)	GR3020036T3 (fr)
NO (1)	NO301747B1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5084274A (en) *	1987-11-17	1992-01-28	Scripps Clinic And Research Foundation	Inhibition of arterial thrombotic occlusion or thromboembolism
JP2739050B2 (ja)	1988-01-28	1998-04-08	ヘキスト薬品工業株式会社	抗血液凝固剤
GB8819607D0 (en) *	1988-08-17	1988-09-21	Wellcome Found	Novel combination
ATE163048T1 (de) *	1989-12-29	1998-02-15	Zymogenetics Inc	Hybrides protein c
US5358932A (en) *	1989-12-29	1994-10-25	Zymogenetics, Inc.	Hybrid protein C
US5571786A (en) *	1990-08-16	1996-11-05	Immuno Aktiengesellschaft	Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) *	1991-01-25	1992-07-31	Fondation Nale Transfusion San	Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
DE59204945D1 (de) *	1991-04-16	1996-02-15	Boehringer Mannheim Gmbh	Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
AT397615B (de) *	1991-05-14	1994-05-25	Immuno Ag	Arzneimittel enthaltend protein c
AT402262B (de) *	1991-06-20	1997-03-25	Immuno Ag	Arzneimittel enthaltend aktiviertes protein c
AT395596B (de) *	1991-06-20	1993-01-25	Immuno Ag	Verfahren zur herstellung von aktiviertem protein c
AT402263B (de) *	1991-06-20	1997-03-25	Immuno Ag	Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
WO1993009807A1 (fr) *	1991-11-18	1993-05-27	The Scripps Research Institute	Procedes d'inhibition de la thrombose par elevation des taux de proteine c activee endogene dans la circulation
JPH05271098A (ja) *	1992-03-26	1993-10-19	Teijin Ltd	活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) *	1993-06-18	1994-12-22	Immuno Ag	Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) *	1993-07-02	1996-05-28	Immuno Aktiengesellschaft	Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) *	1993-10-29	2000-05-22	財団法人化学及血清療法研究所	ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) *	1994-03-25	1996-04-23	Boehringer Mannheim Gmbh	Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE69627191T2 (de) *	1995-06-09	2004-01-08	The Regents Of The University Of Michigan, Ann Arbor	Bradikininanaloge als selektive thrombininhibitoren
ID23176A (id) *	1997-03-24	2000-03-23	Lilly Co Eli	Metoda untuk mengobati gangguan pembuluh darah
US6982249B1 (en)	1997-04-23	2006-01-03	The Regents Of The University Of Michigan	Bradykinin analogs as selective inhibitors of cell activation
WO1998055142A1 (fr) *	1997-06-05	1998-12-10	Eli Lilly And Company	Procede de traitement de troubles thrombotiques
HUP0001237A3 (en)	1997-10-20	2002-01-28	Lilly Co Eli	Methods for treating vascular disorders
US6953568B1 (en)	1998-08-25	2005-10-11	Oklahoma Medical Research Foundation	Targeting of molecules to large vessel endothelium using EPCR
EP1133314B1 (fr)	1998-11-23	2003-02-19	Eli Lilly And Company	Proteine c pour le traitement de drepanocytose et de thalassemie
WO2001056532A2 (fr) *	2000-02-04	2001-08-09	The Scripps Research Institute	Utilisations a des fins neuroprotectrices, antithrombotiques et anti-inflammatoires de la proteine c activee
US7204981B2 (en)	2000-03-28	2007-04-17	Eli Lilly And Company	Methods of treating diseases with activated protein C
CA2410567A1 (fr)	2000-05-24	2001-11-29	Eli Lilly And Company	Preparations et techniques permettant de traiter des hypercoagulations
US7759506B2 (en)	2002-02-25	2010-07-20	Diffusion Pharmaceuticals Llc	Bipolar trans carotenoid salts and their uses
US20040122354A1 (en) *	2002-09-05	2004-06-24	Semba Charles P.	Infusion catheter having an integrated doppler transducer
WO2004056309A2 (fr)	2002-12-05	2004-07-08	Socratech L.L.C.	Activite neuroprotectrice de la proteine c activee independante de son activite anticoagulante
US20070142272A1 (en) *	2003-01-24	2007-06-21	Zlokovic Berislav V	Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2005007820A2 (fr)	2003-07-08	2005-01-27	The Scripps Research Institute	Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite
US9192657B2 (en) *	2003-07-08	2015-11-24	The Scripps Research Institute	Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
JP2008507561A (ja) *	2004-07-23	2008-03-13	ザユニバーシティオブロチェスター	活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
UA95903C2 (ru)	2005-02-24	2011-09-26	Дифьюжен Фармасьютикалз Ллк	Транс-каротиноиды, их синтез, лекарственная форма и применение
US7785857B2 (en) *	2006-08-31	2010-08-31	Saint Louis University	Protein C variant
CA2668187A1 (fr) *	2006-10-31	2008-06-19	The Scripps Research Institute	Schema posologique de proteine c activee et de ses variants presentant une activite anticoagulante reduite
CN101687757A (zh)	2007-04-13	2010-03-31	扩散药品有限公司	双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
KR101875843B1 (ko)	2009-06-22	2018-07-06	디퓨젼 파마슈티컬즈 엘엘씨	확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
KR101891357B1 (ko)	2010-06-02	2018-08-24	디퓨젼 파마슈티컬즈 엘엘씨	양극성 트랜스 카로티노이드의 경구용 제형
AU2013286812B2 (en)	2012-07-04	2017-04-20	Zz Biotech Llc	Treatment of inflammatory skin disorders
PL3131572T3 (pl)	2014-04-16	2022-02-07	Zz Biotech Llc	Analog apc do zastosowania w zaleczaniu rany
PT3137102T (pt)	2014-04-16	2021-09-28	Zz Biotech Llc	Apc para utilização no tratamento de cicatrização cutânea anormal
US11185523B2 (en)	2016-03-24	2021-11-30	Diffusion Pharmaceuticals Llc	Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4766075A (en) *	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
JPS6011427A (ja) *	1983-06-29	1985-01-21	Green Cross Corp:The	血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) *	1983-07-20	1983-08-24	Beecham Group Plc	Compounds
DE3584902D1 (de) *	1984-02-29	1992-01-30	Asahi Chemical Ind	Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU595173B2 (en) *	1985-01-08	1990-03-29	General Hospital Corporation, The	Method and use for site-specific activation of substances
US4775624A (en) *	1985-02-08	1988-10-04	Eli Lilly And Company	Vectors and compounds for expression of human protein C
CA1341228C (fr) *	1985-06-27	2001-05-15	Mark J. Murray	Expression de la proteine c
US5084274A (en) *	1987-11-17	1992-01-28	Scripps Clinic And Research Foundation	Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) *	1987-11-25	1990-05-29	Scripps Clinic And Research Foundation	Method of inhibiting platelet dependent arterial thrombosis

1987
- 1987-11-17 US US07/121,702 patent/US5084274A/en not_active Expired - Lifetime
1988
- 1988-11-15 CA CA000583138A patent/CA1330036C/fr not_active Expired - Lifetime
- 1988-11-16 AT AT88310800T patent/ATE135234T1/de not_active IP Right Cessation
- 1988-11-16 DK DK198806400A patent/DK175704B1/da not_active IP Right Cessation
- 1988-11-16 ES ES88310800T patent/ES2086301T3/es not_active Expired - Lifetime
- 1988-11-16 DE DE3855096T patent/DE3855096T2/de not_active Expired - Lifetime
- 1988-11-16 NO NO885109A patent/NO301747B1/no not_active IP Right Cessation
- 1988-11-16 EP EP88310800A patent/EP0318201B1/fr not_active Expired - Lifetime
- 1988-11-17 JP JP63292222A patent/JP2766986B2/ja not_active Expired - Lifetime
- 1988-11-17 FI FI885331A patent/FI104790B/fi not_active IP Right Cessation
1991
- 1991-10-25 US US07/782,817 patent/US5350578A/en not_active Expired - Lifetime
1996
- 1996-05-27 GR GR960401399T patent/GR3020036T3/el unknown

Also Published As

Publication number	Publication date
GR3020036T3 (en)	1996-08-31
ES2086301T3 (es)	1996-07-01
EP0318201A2 (fr)	1989-05-31
JP2766986B2 (ja)	1998-06-18
DK175704B1 (da)	2005-01-24
DK640088D0 (da)	1988-11-16
DK640088A (da)	1989-05-18
FI885331A0 (fi)	1988-11-17
EP0318201A3 (en)	1990-02-07
FI104790B (fi)	2000-04-14
US5350578A (en)	1994-09-27
FI885331L (fi)	1989-05-18
NO885109D0 (no)	1988-11-16
DE3855096D1 (de)	1996-04-18
JPH01238536A (ja)	1989-09-22
ATE135234T1 (de)	1996-03-15
CA1330036C (fr)	1994-06-07
DE3855096T2 (de)	1996-07-25
US5084274A (en)	1992-01-28
NO885109L (no)	1989-05-18
EP0318201B1 (fr)	1996-03-13

Legal Events

Date	Code	Title	Description
2006-07-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO301747B1 (no)	1997-12-08	Fremgangsmåte for å fremstille aktivert protein C (APC)
Gold et al.	1984	Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Agnelli et al.	1985	A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.
Shebuski et al.	1990	Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
US20090136557A1 (en)	2009-05-28	Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
US5776452A (en)	1998-07-07	Thrombosis agent
NO171344B (no)	1992-11-23	Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
DK167738B1 (da)	1993-12-13	Fremgangsmaade til fremstilling af en oploesning med hoej specifik rumfangsaktivitet af et protein med vaevs-plasminogenaktivator(t-pa)-aktivitet, oploesning der indeholder protein med t-pa-aktivitet, og anvendelsen af oploesningen inden for human- og veterinaermedicinen
Novokhatny et al.	2003	Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis
EP0907724B1 (fr)	2007-03-21	Multimerase purifiee
Schulman	1985	Studies on the medical treatment of deep vein thrombosis
AU623347B2 (en)	1992-05-14	Thrombolytic agent
Markland	1996	Fibrolase, an active thrombolytic enzyme in arterial and venous thrombosis model systems
Moran et al.	1989	The role of thrombolytic therapy in surgical practice
Berridge et al.	1989	Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator
Becker et al.	1990	The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting
JP5236952B2 (ja)	2013-07-17	改善された特性を有するｆｘｉｉｉバリアント
Sharma	1987	Historical overview of antithrombotic and thrombolytic therapy
Pandolfi	1984	Anticoagulants, fibrinolytics, and hemostatics
Pothoulakis et al.	1995	Ancrod for coronary angioplasty
Markland	2012	FIBROLASE, AN ACTIVE THROMBOLYTIC
Weissman et al.	1996	Clinical evaluation of aprotinin
Sandset et al.	1987	EXTRINSIC PATHWAY INHIBITOR (EPI) DURING ELECTUVE SUGERY: A COMPARISON WITH OTHER COAGULATION INHIBITORS
Aogaichi et al.	1995	D. Indirect Thrombolytic Agents
Ouriel	2005	Peripheral arterial thrombolysis